Morgan Stanley Bellerophon Therapeutics, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.68 - $12.39 $612,975 - $11.2 Million	-901,434 Reduced 100.0%	33 $0
Q1 2023 May 15, 2023	BUY	$0.9 - $7.89 $809,991 - $7.1 Million	899,990 Added 60933.65%	901,467 $7.11 Million
Q4 2022 Feb 14, 2023	BUY	$0.67 - $1.2 $4 - $8	7 Added 0.48%	1,477 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.96 - $1.69 $2 - $5	-3 Reduced 0.2%	1,470 $2,000
Q2 2022 Oct 27, 2022	SELL	$0.85 - $2.36 $613 - $1,703	-722 Reduced 32.89%	1,473 $2,000
Q2 2022 Aug 15, 2022	SELL	$0.85 - $2.36 $613 - $1,703	-722 Reduced 32.89%	1,473 $2,000
Q1 2022 Oct 27, 2022	BUY	$1.82 - $3.24 $1,314 - $2,339	722 Added 49.02%	2,195 $5,000
Q1 2022 May 13, 2022	SELL	$1.82 - $3.24 $5,991 - $10,666	-3,292 Reduced 60.0%	2,195 $5,000
Q4 2021 Feb 14, 2022	BUY	$2.36 - $4.05 $8,647 - $14,839	3,664 Added 200.99%	5,487 $17,000
Q3 2021 Nov 15, 2021	BUY	$3.75 - $4.86 $6,836 - $8,859	1,823 New	1,823 $7,000

44K

Ticker BLPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,545,450
Market Cap $95.5K
Description
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.